The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia

American Journal of Hematology

Volumn 81, Issue 8, 2006, Pages 631-633

  Pamuk, Gülsüm Emel ^a,b   Turgut, Burhan ^a   Demir, Muzaffer ^a   Tezcan, Fatma ^a   Vural, Özden ^a  

^a TRAKYA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Autoimmune hemolytic anemia; Chronic lymphocytic leukemia; Rituximab

Indexed keywords

BILIRUBIN; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ANOREXIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; BLOOD SMEAR; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COOMBS TEST; FATIGUE; FOLLOW UP; HEMATOCRIT; HEMOLYSIS; HEPATOMEGALY; HUMAN; LEUKOCYTE COUNT; LYMPHADENOPATHY; MALE; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE COUNT; WEIGHT REDUCTION;

AGED; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; TREATMENT OUTCOME;

EID: 33745987588     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20671     Document Type: Article

References (20)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
2. Mauro F, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia. Clinical, therapeutic and prognostic features. Blood 2000;95:2786-2792.
3. Kalil N, Cheson BD. Management of chronic lymphocytic leukemia. Drugs Aging 2000;16:9-27.
4. Liu NS, O'Brien S. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Med Oncol 2004;21:297-304.
5. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-2095.
6. Seipelt G, Böhme A. Koschmieder S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolyphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol 2001;80:170-173.
7. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567-1574.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
9. Maloney DG, Smith B, Appelhaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines (abs). Blood 1996;88:637.
10. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
11. Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leukemia Lymphoma 2003;44:1951-1955.
12. Shvidel L, Shtalrid M, Berrebi A. Intractable autoimmune hemolytic anemia in B cell chronic lymphocytic leukemia resolved by rituximab. Leukemia Lymphoma 2004;45:1493-4.
13. Chemnitz J, Draube A, Diehl V, Wolf J. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab. Am J Hematol 2002;69:232-233.
14. Iannitto E, Ammatuna E, Marino C, Cirrincione S, Greco G, Mariani G. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolytic anemia to anti-CD20 monoclonal antibody. Blood 2002;99:1096-1097.
15. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002;99:1092-1094.
16. Narra K, Borghaei H, Al-Saleem T, Hoglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leukocyte Res 2006;30:109-114.
17. Pantelidou D, Tsatalas C, Margaritis D, Kaloutsi V, Spanoudakis E, Bourikas G. Anti-CD 20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia. Hematol J 2004;5:546-547.
18. Okamoto M, Nakano S, Namura K, Yamada N, Uchida R. Fuchida S, Okano A, Ochiai N, Shimazaki C. CD5-negative chronic lymphocytic leukemia with indolent clinical course and autoimmune thrombocytopenia, succesfully treated with rituximab. Am J Hematol 2004;77:413-415.
19. Fernandez MJ, Llopis I, Pastor E, Real E, Grau E. Immune thrombocytopenia induced by fludarabine successfully treated with rituximab. Haematologica 2003;88:ELT02.
20. Paydas S. Fludatabine-induced hemolytic anemia: successful treatment by rituximab. Hematol J 2004;5:81-83.